Days indicated are after tumor challenges. Mice were injected with 100 μg of αB7-H1 (clone 10F.9G2), αPD-1 (clone RMP1-14) or αCTLA-4 (clone 9H10, all from BioXCell) monoclonal antibodies intraperitoneally (i.p.) on days 4, 7 and 12. αCD25 (250 μg, clone PC-61.5.3, BioXCell) was administered i.p. on day 2. Denileukin diftitox (DD, Eisai), a fusion protein of diphtheria toxin and human interleukin-2 (IL-2) (18 (link)), that depletes mouse Tregs to treat distinct carcinomas (15 (link),16 (link),19 (link)), was given 5 μg i.p. every 4 days for EL4 challenge, and every 5 days for B16 and ID8agg challenge. Foxp3DTR mice engineered to allow Treg-specific depletion using diphtheria toxin (15 (link)) were injected i.p. with 1 μg/kg diphtheria toxin every 3 days starting on day 4. Rapamycin (LC Laboratories) or vehicle control (0.25% Tween 80 + 0.25% PEG400) was given i.p. daily for 5 consecutive days/week at indicated doses starting on day 4, for times indicated. Rapamycin at 1–8 mg/kg is defined as typical, and 0.075 mg/kg as low dose (LD).
Protocol detail
Immunomodulatory Therapy for Tumor Control
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
A protein
Carcinomas
Clone
Denileukin diftitox
Diphtheria toxin
Human
Interleukin 2
Mice
Monoclonal antibodies
Peg400
Rapamycin
Tumor
Tween
Corresponding Organization : The University of Texas Health Science Center at San Antonio
Other organizations : Central South University
Top 5 similar protocols
Protocol cited in 1 other protocol
Variable analysis
independent variables
- αB7-H1 (clone 10F.9G2) monoclonal antibody
- αPD-1 (clone RMP1-14) monoclonal antibody
- αCTLA-4 (clone 9H10) monoclonal antibody
- αCD25 (clone PC-61.5.3) monoclonal antibody
- Denileukin diftitox (DD, Eisai)
- Diphtheria toxin (in Foxp3^DTR mice)
- Rapamycin
- Vehicle control (0.25% Tween 80 + 0.25% PEG400)
- Not explicitly mentioned
- Days indicated are after tumor challenges
- 100 μg of monoclonal antibodies administered intraperitoneally (i.p.) on days 4, 7 and 12
- 250 μg of αCD25 administered i.p. on day 2
- 5 μg of DD administered i.p. every 4 days for EL4 challenge, and every 5 days for B16 and ID8agg challenge
- 1 μg/kg of diphtheria toxin administered i.p. every 3 days starting on day 4 in Foxp3^DTR mice
- Rapamycin or vehicle control administered i.p. daily for 5 consecutive days/week at indicated doses starting on day 4, for times indicated
- Not explicitly mentioned
- Vehicle control (0.25% Tween 80 + 0.25% PEG400)
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!